Stockis, Armel
UCB Pharma (Belgium)
3 papers on CoChatORCID 0000-0002-0815-5264
Most cited papers
- Verified
Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (SV 2A) ligand with preclinical evidence of high brain permeability and fast onset of action
Nicolas, J., Hannestad, J., Holden, D., Kervyn, S., Nabulsi, N., Tytgat, D., Huang, Y., Chanteux, H., Staelens, L., Matagne, A., et al. (2016) · Epilepsia
Epilepsy research and treatmentBarrier Structure and Function Studies
Cited by 169
- Verified
Assessment of a white matter reference region for 11 C-UCB-J PET quantification
Rossano, S., Toyonaga, T., Finnema, S. J., Naganawa, M., Lu, Y., Nabulsi, N., Ropchan, J., De Bruyn, S., Otoul, C., Stockis, A., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism
Medical Imaging Techniques and ApplicationsAdvanced MRI Techniques and Applications
Cited by 126
- Verified
A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers
Finnema, S. J., Rossano, S., Naganawa, M., Henry, S., Gao, H., Pracitto, R., Maguire, R. P., Mercier, J., Kervyn, S., Nicolas, J., et al. (2019) · Epilepsia
Epilepsy research and treatmentNeuroscience and Neuropharmacology Research
Cited by 65
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free